Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sibylle Gaisser

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|December 15, 2010
[The role of biotechnology in pharmaceutical drug design]Sibylle Gaisser, Michael Nusser
Systems and Synthetic Biology|October 10, 2009
Shaping the science-industry-policy interface in synthetic biologySibylle Gaisser, Thomas Reiss
Public Understanding of Science (Bristol, England)|May 17, 2012
Synthetic biology in the view of European public funding organisationsLei Pei, Sibylle Gaisser, Markus Schmidt
Nature|March 28, 2009
The phantom menace of gene patentsSibylle Gaisser, Michael M Hopkins, Kathleen Liddell, et al.
EMBO Reports|July 29, 2009
Making the most of synthetic biology. Strategies for synthetic biology development in EuropeSibylle Gaisser, Thomas Reiss, Astrid Lunkes, et al.
Personalized Medicine|May 23, 2018
EU policies in personalized medicine-related technologiesSibylle Gaisser, Etienne Vignola-Gagné, Bärbel Hüsing, et al.
BMC Public Health|May 8, 2026
Policy challenges in the provision of COVID-19 border screening: evidence from eight countriesJames Bates, Joshua R Moon, Sibylle Gaisser, et al.
Nature Biotechnology|April 8, 2006
Putting pharmacogenetics into practiceMichael M Hopkins, Dolores Ibarreta, Sibylle Gaisser, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|December 15, 2010
[The role of biotechnology in pharmaceutical drug design]Sibylle Gaisser, Michael Nusser
Systems and Synthetic Biology|October 10, 2009
Shaping the science-industry-policy interface in synthetic biologySibylle Gaisser, Thomas Reiss
Public Understanding of Science (Bristol, England)|May 17, 2012
Synthetic biology in the view of European public funding organisationsLei Pei, Sibylle Gaisser, Markus Schmidt
Nature|March 28, 2009
The phantom menace of gene patentsSibylle Gaisser, Michael M Hopkins, Kathleen Liddell, et al.
EMBO Reports|July 29, 2009
Making the most of synthetic biology. Strategies for synthetic biology development in EuropeSibylle Gaisser, Thomas Reiss, Astrid Lunkes, et al.
Personalized Medicine|May 23, 2018
EU policies in personalized medicine-related technologiesSibylle Gaisser, Etienne Vignola-Gagné, Bärbel Hüsing, et al.
BMC Public Health|May 8, 2026
Policy challenges in the provision of COVID-19 border screening: evidence from eight countriesJames Bates, Joshua R Moon, Sibylle Gaisser, et al.
Nature Biotechnology|April 8, 2006
Putting pharmacogenetics into practiceMichael M Hopkins, Dolores Ibarreta, Sibylle Gaisser, et al.
Pageof 1